Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 11, 2023

BUY
$138.31 - $165.87 $202,485 - $242,833
1,464 New
1,464 $237,000
Q1 2022

Apr 27, 2022

SELL
$131.98 - $163.75 $2,111 - $2,620
-16 Reduced 1.03%
1,531 $248,000
Q4 2021

Jan 14, 2022

BUY
$107.43 - $135.93 $166,194 - $210,283
1,547 New
1,547 $209,000
Q3 2021

Oct 20, 2021

SELL
$106.4 - $120.78 $229,079 - $260,039
-2,153 Closed
0 $0
Q2 2021

Jul 20, 2021

BUY
$105.21 - $117.21 $226,517 - $252,353
2,153 New
2,153 $243,000
Q1 2021

Apr 20, 2021

SELL
$102.3 - $112.62 $228,640 - $251,705
-2,235 Closed
0 $0
Q4 2020

Jan 27, 2021

BUY
$80.49 - $108.67 $179,895 - $242,877
2,235 New
2,235 $239,000
Q3 2020

Nov 02, 2020

SELL
$85.91 - $100.83 $203,434 - $238,765
-2,368 Closed
0 $0
Q2 2020

Jul 28, 2020

BUY
$73.37 - $98.18 $173,740 - $232,490
2,368 New
2,368 $232,000
Q1 2020

Apr 27, 2020

SELL
$64.5 - $97.79 $152,736 - $231,566
-2,368 Closed
0 $0
Q4 2019

Jan 29, 2020

BUY
$72.13 - $90.25 $170,803 - $213,712
2,368 New
2,368 $210,000
Q2 2019

Aug 08, 2019

SELL
$65.7 - $83.98 $166,221 - $212,469
-2,530 Closed
0 $0
Q1 2019

Apr 26, 2019

SELL
$77.14 - $90.79 $848 - $998
-11 Reduced 0.43%
2,530 $204,000
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $4,712 - $5,238
53 Added 2.13%
2,541 $240,000
Q2 2018

Aug 03, 2018

SELL
$89.78 - $106.23 $10,055 - $11,897
-112 Reduced 4.31%
2,488 $231,000
Q1 2018

May 09, 2018

SELL
$92.01 - $123.21 $1,932 - $2,587
-21 Reduced 0.8%
2,600 $246,000
Q4 2017

Jan 30, 2018

SELL
$89.56 - $98.21 $3,134 - $3,437
-35 Reduced 1.32%
2,621 $253,000
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $185,521 - $236,968
2,656
2,656 $236,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $353B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Coho Partners, Ltd. Portfolio

Follow Coho Partners, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coho Partners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Coho Partners, Ltd. with notifications on news.